Canada Spends Logo

Explore our Budget 2026 analysis

Grant: DRA : Canada Graduate Research Scholarship - Doctoral Program (CGRS D)

University of Toronto

$120,000.00

CRISPR and Artificial Intelligence-designed Retron (CAIR) System Enables Precise Gene Correction of CFTR Nonsense Mutations in Cystic Fibrosis

FY 2025-26

Summary
Cystic fibrosis (CF) is a rare genetic disorder affecting over 70,000 individuals worldwide, caused by mutations in the CFTR gene, which encodes a chloride channel essential for fluid balance in epithelial tissues. While current therapies such as Trikafta have improved outcomes for patients with missense mutations, they remain ineffective for nonsense mutations, which account for ~10% of cases. The G542X mutation is particularly prevalent, affecting ~4.6% of patients. Gene editing offers a promising avenue to directly correct such disease-causing mutations and achieve durable therapeutic benefit. Recent studies have demonstrated proof-of-concept correction in the lung using co-delivery of CRISPR/Cas9 mRNA with linear single-stranded DNA donors via lipid nanoparticles (LNPs), yet editing efficiencies remain low (<2%) due to challenges in co-delivering RNA and DNA in vivo. Bacterial retron systems offer a unique solution, producing multicopy single-stranded DNA (msDNA) covalently linked to their RNA template, which can serve as an intracellular HDR donor when paired with CRISPR/Cas9. However, limited msDNA output in mammalian cells constrains their translational potential. To overcome this barrier, we propose CRISPR and Artificial Intelligence-designed Retron (CAIR) system, leveraging artificial intelligence (AI) foundation models trained on raw protein sequence space to rapidly identify and engineer retrons with high msDNA production in mammalian cells. By integrating AI-guided retron design with optimized delivery via LNPs, CAIR aims to achieve efficient, precise genome correction of clinically relevant CFTR nonsense mutations such as G542X, providing a transformative strategy for patients who currently lack effective treatment options.
Program
DRA : Canada Graduate Research Scholarship - Doctoral Program (CGRS D)
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
559703
Name
Gong Fanglin
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Circulatory and Respiratory Health
Theme2
Biomedical
Prcname2
DT1 (Biomedical and/or Clinical Research) CGRS Doctoral
Projecttitle
CRISPR and Artificial Intelligence-designed Retron (CAIR) System Enables Precise Gene Correction of CFTR Nonsense Mutations in Cystic Fibrosis
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$120,000
Cihrequipment2
$0
Programname2
DRA : Canada Graduate Research Scholarship - Doctoral Program (CGRS D)
Keyworddelim
Artificial Intelligence / Computational Biology; Cystic Fibrosis; Gene Editing; Lipid Nanoparticle; Protein Engineering
Abstract
Cystic fibrosis (CF) is a rare genetic disorder affecting over 70,000 individuals worldwide, caused by mutations in the CFTR gene, which encodes a chloride channel essential for fluid balance in epithelial tissues. While current therapies such as Trikafta have improved outcomes for patients with missense mutations, they remain ineffective for nonsense mutations, which account for ~10% of cases. The G542X mutation is particularly prevalent, affecting ~4.6% of patients. Gene editing offers a promising avenue to directly correct such disease-causing mutations and achieve durable therapeutic benefit. Recent studies have demonstrated proof-of-concept correction in the lung using co-delivery of CRISPR/Cas9 mRNA with linear single-stranded DNA donors via lipid nanoparticles (LNPs), yet editing efficiencies remain low (<2%) due to challenges in co-delivering RNA and DNA in vivo. Bacterial retron systems offer a unique solution, producing multicopy single-stranded DNA (msDNA) covalently linked to their RNA template, which can serve as an intracellular HDR donor when paired with CRISPR/Cas9. However, limited msDNA output in mammalian cells constrains their translational potential. To overcome this barrier, we propose CRISPR and Artificial Intelligence-designed Retron (CAIR) system, leveraging artificial intelligence (AI) foundation models trained on raw protein sequence space to rapidly identify and engineer retrons with high msDNA production in mammalian cells. By integrating AI-guided retron design with optimized delivery via LNPs, CAIR aims to achieve efficient, precise genome correction of clinically relevant CFTR nonsense mutations such as G542X, providing a transformative strategy for patients who currently lack effective treatment options.
Competitiondate
202511
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Gong, Fanglin
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $120,000~ $0~